We're loading the full news article for you. This includes the article content, images, author information, and related articles.
Pharmaceutical giant Eli Lilly has announced promising trial results for a once-daily obesity pill, orforglipron, that helps patients maintain weight loss without weekly injections—a potential game-changer for tackling a growing health crisis in Kenya.

A new pill could soon offer an alternative to the needle for thousands of Kenyans managing obesity and type 2 diabetes. Pharmaceutical firm Eli Lilly revealed on Thursday that its experimental daily tablet, orforglipron, successfully helped patients keep off weight they had previously lost using powerful injectable drugs.
This development is significant for Kenya, where non-communicable diseases are a rising threat. With obesity affecting roughly one in ten Kenyans and central obesity impacting over a third of the population, the need for more accessible and convenient long-term treatments is critical. Injectable drugs like Ozempic are available but can be costly and cumbersome for daily life.
The latest study, named ATTAIN-MAINTAIN, tested orforglipron not as an initial weight-loss tool, but as a maintenance therapy. Participants who had already lost significant weight over 72 weeks with injectable medicines like Wegovy or Zepbound were switched to the daily pill.
The results showed that those who took orforglipron largely maintained their weight loss over the following year, whereas those on a placebo regained significant weight. This positions the pill as a crucial follow-up treatment, addressing the common challenge of weight regain after stopping GLP-1 injections.
In Kenya, the burden of diseases linked to obesity is growing. Studies show a strong association between excess weight and conditions like hypertension and dyslipidemia. Furthermore, approximately 4.5% of the population lives with diabetes, a figure that is higher in urban centres like Nairobi. For many, the high cost of injectable treatments, which can be as much as KES 50,000 per shot, is a major barrier to care.
While the price of orforglipron has not been set, oral medications are often cheaper to produce and distribute than injectables. This could make it a more sustainable option for the Kenyan healthcare system and for patients managing their weight as a chronic condition. The Pharmacy and Poisons Board (PPB) has previously issued warnings about the misuse of injectable weight-loss drugs, highlighting the need for properly managed and accessible alternatives.
Eli Lilly has already submitted orforglipron for approval by the U.S. Food and Drug Administration (FDA), with a decision possible within weeks. If approved, it would join a competitive market for obesity treatments. While analysts note that orforglipron may be less potent for initial, rapid weight loss compared to top-tier injections, its strength lies in convenience and long-term maintenance.
As Kenneth Custer, an executive at Lilly, noted, "Sustaining weight loss remains a significant challenge for many." For Kenyans battling the chronic disease of obesity, a simple, effective daily pill could represent not just a medical breakthrough, but a more manageable path to long-term health.
Keep the conversation in one place—threads here stay linked to the story and in the forums.
Other hot threads
E-sports and Gaming Community in Kenya
Active 7 months ago
Popular Recreational Activities Across Counties
Active 7 months ago
The Role of Technology in Modern Agriculture (AgriTech)
Active 7 months ago
Investing in Youth Sports Development Programs
Active 7 months ago